Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Knight Therapeutics Inc. (T:GUD)

Business Focus: Specialty & Advanced Pharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for GUD within the last 6 months
See all filings within the past 6 months

Company News

May 29, 2020 17:01 ET
Knight Therapeutics Inc. Announces Further Update on Extension of First Quarter 2020 Filings due to COVID-19
Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the  “Company”), a leading pan-American (ex USA) specialty pharmaceutical company, announced today, further to its news release dated April 30, 2020, that  as a result of the COVID-19 impact, Knight...
Read full article
May 27, 2020 17:01 ET
Knight to Present at the Jefferies 2020 Virtual Global Healthcare Conference
Knight Therapeutics Inc. (TSX:  GUD), a leading pan-American (ex- US)  specialty pharmaceutical company, announced today that Samira Sakhia, President, is scheduled to present at the Jefferies 2020 Virtual Global Healthcare Conference on Wednesday,...
Read full article
See more news stories

Valuation Ratios

Price to Sales - TTM
Price to Book - most recent quarter
Price to Cash Flow per share - TTM
Price to Free Cash Flow per share - TTM
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
May 15, 20203,756,581-25,735
Apr 30, 20203,782,316-82,563
Apr 15, 20203,864,879102,676
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Knight Therapeutics Inc is a Canada-based specialty pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices. The Company's products are ILUVIEN Fluocinolone acentonid, Nerlynx Neratinib Tablets, Burinex Bumetanide, Probuphine Buprenorphine implant and Movantik Naloxegol.

See business summary



Search (past week) for $GUD.CA

  • No tweets found